Everything below concerns obesity research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
The grant was intended to support research into the interactions of hydrogen with palladium, nickel or platinum under extreme conditions. In March 2013 Graham K. Hubler, a nuclear physicist who worked for the Naval Research Laboratory for 40 years, was named director. One of the SKINR projects is to replicate a 1991 experiment in which a professor associated with the project, Mark Prelas, says bursts of millions of neutrons a second were recorded, which was stopped because "his research account had been frozen". He claims that the new experiment has already seen "neutron emissions at similar levels to the 1991 observation". In May 2016, the United States House Committee on Armed Services, in its report on the 2017 National Defense Authorization Act, directed the Secretary of Defense to "provide a briefing on the military utility of recent U.S. industrial base LENR advancements to the House Committee on Armed Services by September 22, 2016".
=== Enzyme coagulants === Among enzymes that have been shown to produce tofu are papain, and alkaline and neutral proteases from microorganisms. Papain, moreover, has been studied as a gelling agent to produce "instant tofu" from soy protein isolate and soy glycinin (11S) protein. Contemporary tofu manufacturers may choose to use one or more of these coagulants since each plays a role in producing the desired texture in the finished tofu. Different textures result from different pore sizes and other microscopic features in the tofu produced using each coagulant. The coagulant mixture is dissolved in water, and the solution is then stirred into boiled soy milk until the mixture curdles into a soft gel. Coagulants are typically added at concentrations between 1.5 and 5.0 g/kg. In all coagulants consisting of calcium or magnesium salts, the positive double-bonded ions of the calcium or magnesium are responsible for the coagulation of the soy proteins which become part of the tofu, thereby enhancing its nutritional value. Only 1 part per 1000 of the tofu eaten is coagulant; most of the coagulant reacts with soy protein and is broken down into ions. The non-reactive portion dissolves in the soy whey and is discarded. Although tartness is sometimes desired in dessert tofu, the acid used in flavoring is usually not the primary coagulant, since concentrations sufficiently high to induce coagulation negatively affect the flavor or texture of the resulting tofu.
==== MeSH D13.570.800 – ribonucleosides ==== MeSH D13.570.800.096 – adenosine MeSH D13.570.800.096.250 – adenosine-5'-(n-ethylcarboxamide) MeSH D13.570.800.096.262 – s-adenosylhomocysteine MeSH D13.570.800.096.264 – s-adenosylmethionine MeSH D13.570.800.096.300 – 2-chloroadenosine MeSH D13.570.800.096.300.200 – cladribine MeSH D13.570.800.096.500 – isopentenyladenosine MeSH D13.570.800.096.630 – phenylisopropyladenosine MeSH D13.570.800.286 – cytidine MeSH D13.570.800.286.300 – azacitidine MeSH D13.570.800.330 – dichlororibofuranosylbenzimidazole MeSH D13.570.800.410 – formycins MeSH D13.570.800.410.200 – coformycin MeSH D13.570.800.453 – guanosine MeSH D13.570.800.453.500 – nucleoside q MeSH D13.570.800.573 – inosine MeSH D13.570.800.573.130 – didanosine MeSH D13.570.800.573.450 – inosine pranobex MeSH D13.570.800.573.900 – thioinosine MeSH D13.570.800.573.900.500 – methylthioinosine MeSH D13.570.800.790 – ribavirin MeSH D13.570.800.810 – showdomycin MeSH D13.570.800.840 – toyocamycin MeSH D13.570.800.850 – tubercidin MeSH D13.570.800.892 – uridine MeSH D13.570.800.892.176 – azauridine MeSH D13.570.800.892.250 – 3-deazauridine MeSH D13.570.800.892.628 – pseudouridine MeSH D13.570.800.892.800 – tetrahydrouridine MeSH D13.570.800.892.829 – thiouridine
an [acyl-carrier-protein] + dodecanoate This enzyme belongs to the family of hydrolases, specifically those acting on thioester bonds. The systematic name is dodecanoyl-[acyl-carrier-protein] hydrolase. Other names in common use include lauryl-acyl-carrier-protein hydrolase, dodecanoyl-acyl-carrier-protein hydrolase, dodecyl-acyl-carrier protein hydrolase, and dodecanoyl-[acyl-carrier protein] hydrolase.
A limited theatrical run began on June 10, 2010, and the film was released on DVD and Blu-ray in the U.S. and Canada on June 29, 2010. The film explores the band's influence on popular music and the reasons why that influence has been underrepresented over the years. That is done via interviews with popular musicians, music industry professionals, and the band members themselves. On June 25, 2010, Rush received a star on the Hollywood Walk of Fame at 6752 Hollywood Boulevard. Critical acclaim continued to mount for Rush in 2010 when, on September 28, Classic Rock announced that Rush would receive 2010's Living Legends award at the Marshall Classic Rock Roll of Honour Awards in the UK. The award was presented on November 10, 2010. On September 29, Billboard.com announced that Rush would also receive the 2010 Legends of Live award for significant and lasting contributions to live music and the art of performing live and reaching fans through the concert experience. The award was presented at the Billboard Live Music Awards on November 4, 2010. In 2013, the Canadian government honoured Rush with a first class "permanent" postage stamp, the equivalent of a "Forever" stamp in the US, featuring the iconic "Starman" Rush logo. The band members were made Officers of the Order of Canada in 1996. In May 2012, the band received the Governor General's Performing Arts Award for Lifetime Artistic Achievement at a ceremony at Rideau Hall, followed the next by a gala at the National Arts Centre celebrating the award recipients.
Sources: en.wikipedia.org
In May 1991, the PDRE (1987-1991) was overthrown by forces consisting of the TPLF and the TPLF-controlled EPRDF with the promise that a recognition of human rights, democracy, the liberalization of the economic sector, and political rehabilitation were soon to follow. The PDRE, the country's newest civilian regime, was actually dominated by leaders of the preceding Derg (1974-1987) a military junta led by Mengistu Haile Mariam that seized power by overthrowing the long-ruling Emperor Haile Selassie I in 1974. The Derg (meaning "committee" or "council") and its leaders were known for dramatically restructuring the country's political and economic institutions, often through the use of suppression and fear, while transforming the central government's role in domestic affairs. Programs such as the extensive villagization schemes carried out in various parts of the country further served as a testament to the regime's commitment to radical reform measures. Once in power, the leaders of the PDRE continued pursuing their aims as former Derg leaders, such as by resuming forced resettlement programs that were deemed nonviable by many and were ultimately met with a considerable amount of international criticism. Scholars have noted that the fall of the PDRE was largely made possible by the loss of both financial and military support from the dwindling Soviet Union, which had previously backed the Derg following their seizure of power in 1974.
=== Solar cells === Selenium was used as the photoabsorbing layer in the first solid-state solar cell, which was demonstrated by the English physicist William Grylls Adams and his student Richard Evans Day in 1876. Only a few years later, Charles Fritts fabricated the first thin-film solar cell, also using selenium as the photoabsorber. As silicon solar cells emerged in the 1950s, research on selenium thin-film solar cells declined. The record efficiency of 5.0% demonstrated by Tokio Nakada and Akio Kunioka in 1985 remained unchanged for more than 30 years. In 2017, researchers from IBM achieved a new record efficiency of 6.5% by redesigning the device structure. Following this achievement, selenium has gained renewed interest as a wide bandgap photoabsorber with the potential of being integrated in tandem with lower bandgap photoabsorbers. In 2024, the first selenium-based tandem solar cell was demonstrated, showcasing a selenium top cell monolithically integrated with a silicon bottom cell. A significant deficit in the open-circuit voltage is currently the limiting factor to further improve the efficiency, necessitating defect-engineering strategies for selenium thin-films to enhance the carrier lifetime. Recent theoretical studies using first-principles defect calculations have shown that selenium exhibits intrinsic point defect tolerance, suggesting that interfaces and extended defects are the primary factors limiting device performance.
== Side effects == Side effects of THC can include red eyes, dry mouth, drowsiness, short-term memory impairment, difficulty concentrating, ataxia, increased appetite, anxiety, paranoia, psychosis (i.e., hallucinations, delusions), decreased motivation, and time dilation, among others. Chronic usage of THC may result in cannabinoid hyperemesis syndrome (CHS), a condition characterized by cyclic nausea, vomiting, and abdominal pain that may persist for months to years after discontinuation.
The offerings of Patient CROs (Clinical CROs) comprise more than 30 tasks addressing the clinical part of pharmaceutical development at the interface between drugs, physicians, hospitals, and patients, such as the clinical development and selection of lead new drug compounds. As clinical trials represent the largest expense in pharmaceutical research, the market for Patient CROs is larger than for their product counterparts. Thus, the sales of the top tier firms, such as Charles River Laboratories, Fortrea, Parexel, PPD, Quintiles Transnational, all USA, and TCG Lifescience, India, are in the $1–$2 billion range, whereas the largest Product CROs have revenues of a few 100 million dollars.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.